Cloud DX Granted New Patent for Pulsewave 2.0 Vital Sign Monitor

Rhea-AI Summary

Cloud DX has announced the issuance of a second patent for its Pulsewave 2.0 Vital Sign Monitor, allowing it to detect blood pressure, heart rate, and respiratory status in a single, clinical-grade reading of 60 seconds. This patent strengthens the company’s position in the Medical Metaverse and enhances data accuracy for telehealth applications. The device operates autonomously and can connect to the internet, facilitating easy data transfer to healthcare providers. This milestone comes during a record-breaking quarter for the company, showcasing its innovative approach to virtual healthcare.

Positive

• Second patent for Pulsewave 2.0 enhances data protection and innovation.
• Pulsewave 2.0 offers clinical-grade accuracy for vital sign monitoring.
• Strengthens Cloud DX's offerings in the expanding Medical Metaverse.

Negative

• None.

Breakthrough technology can determine respiratory status in simple 60 second reading

News in Summary

• Cloud DX's Pulsewave 2.0 receives a second patent as the only blood pressure monitor to also detect respiratory rate and status
• This patent protects the methods of assessing key vital-signs including blood pressure, heart rate and respiratory status with hospital level accuracy
• Pulsewave 2.0 strengthens the company's Medical Metaverse offerings by Xtended Reality division

KITCHENER, ON / ACCESSWIRE / March 15, 2022 / Cloud DX (TSXV:CDX) (OTC:CDXFF), a leading Virtual Care platform, announces the issuance of a new patent for its upcoming Pulsewave 2.0 Vital Sign Monitor. The wrist-worn device stands to be the first at home clinical-grade vital signs monitor to capture diagnostic-quality blood pressure, heart rate, heartbeat irregularities, and respiration status simultaneously. This is the second patent for the Pulsewave 2.0 platform and this award arrives during the company's record-breaking quarter.

US patent 11,272,859 entitled ‘System and Method of Determining Respiratory Status From Oscillometric Data', strengthens the protection of Cloud DX's innovative and novel methods used to determine respiratory status. Building upon the device's initial US patent 11,006,843,which depicts the concept of using oscillometric data to determine respiration rate. This patent protects the methods developed to analyze data in determining respiratory status, beyond just respiratory rate. The company congratulates inventors Vesal Badee, Sara Ross-Howe, Josh Haid, Lamiaa Amzil, Cezar Morun, and Bonghun Shin, all members of the Research and Development team at Cloud DX.

Lead inventor and Cloud DX Biomedical Data Scientist, Vesal Badaee, states "There are plenty of digital health wearables in the market. Most, however, are limited in the quality of data they provide. This can frustrate doctors and healthcare professionals when users want to rely on them. In medicine, clinical-grade vitals are required for diagnostics or medical direction; Cloud DX is driving the transition in bringing clinical-grade wearables into the consumer space, from hospitals and clinics to our homes. This second patent on our next-generation Pulsewave underlines the innovation we're producing at Cloud DX. The team and I are proud to be a part of this Virtual Care transition."

"With the Medical Metaverse and the Virtual Care movements growing the need for home-based diagnostics grows ever more prominent," added Robert Kaul, CEO and Founder of Cloud DX. He continued, "Together these technologies create an all-encompassing model of care improves access to healthcare and can expedite accurate clinician decision making. The ability to accurately capture patient vitals anywhere in the world, even in most remote locations, and transfer that data directly to their doctor or care team means primary care teams can make better clinical decisions, potentially remove the need for an in-person doctor visit, or even circumvent an emergent care visit. To put it simply, the connected ecosystem means better patient outcomes, closer circles of care, and more economical for providers and payers."

How Pulsewave 2.0 breathing rate technology works

• Cloud DX's Pulsewave vital signs monitor is worn on a patient's wrist, and oscillometric pulse waveforms are obtained as the cuff deflates, obtaining pulse wave signals and artifact signals over multiple patient breaths.
• Pulsewave software analyzes these signals producing an envelope of pulse waveforms as well as a frequency modulated sequence of pulses at various time intervals containing breathing rate data.
• Pulsewave 2.0 operates autonomously but can also be connected to the internet. When connected, clinicians receiving the data can derive additional biological metrics via the Cloud Diagnostics® online platform.

About Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health ^TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner to Medtronic Canada.

Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx

_{Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.}

Social Links

Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE: Cloud DX Inc.

View source version on accesswire.com:
https://www.accesswire.com/693178/Cloud-DX-Granted-New-Patent-for-Pulsewave-20-Vital-Sign-Monitor

FAQ

What is the significance of Cloud DX's second patent for Pulsewave 2.0?

The second patent enhances the protection of innovative methods for vital sign monitoring, boosting the product's market viability and competitive edge.

How does Pulsewave 2.0 improve telehealth services?

Pulsewave 2.0 captures diagnostic-quality vital signs, enabling remote monitoring and potentially reducing the need for in-person medical visits.

What vital signs can Pulsewave 2.0 monitor?

Pulsewave 2.0 can monitor blood pressure, heart rate, and respiratory status simultaneously with clinical-grade accuracy.

When was the patent for Pulsewave 2.0 issued?

The patent was announced on March 15, 2022.

What does Cloud DX aim to achieve with its Medical Metaverse offerings?

Cloud DX aims to provide improved patient outcomes and more accessible healthcare through innovative virtual care solutions.